Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West
Inogen (NASDAQ: INGN) announced changes to its Board of Directors, effective January 2025. Mira Kirti Sahney has been appointed as a new board member, while Tom West will retire after serving since April 2023.
Sahney brings significant medical device industry experience, currently serving on Claria Medical's board and previously as President of Medtronic's Pelvic Health Operating Unit (2021-2024). Her experience includes roles as CEO of Hyalex Orthopaedics, leadership positions at Smith + Nephew, and co-founding Myomo. She holds multiple engineering degrees from University of Michigan and Stanford, plus an MBA from MIT.
In her new role, Sahney will join Inogen's Compliance Committee and the Nominating and Governance Committee. The appointment aims to strengthen Inogen's position as a global leader in respiratory care.
Inogen (NASDAQ: INGN) ha annunciato cambiamenti al suo Consiglio di Amministrazione, a partire da gennaio 2025. Mira Kirti Sahney è stata nominata nuova membro del consiglio, mentre Tom West andrà in pensione dopo aver servito dal aprile 2023.
Sahney porta con sé una significativa esperienza nel settore dei dispositivi medici, attualmente fa parte del consiglio di Claria Medical e in precedenza è stata Presidente dell'Unità Operativa Pelvica di Medtronic (2021-2024). La sua esperienza include ruoli come CEO di Hyalex Orthopaedics, posizioni dirigenziali in Smith + Nephew e la co-fondazione di Myomo. Ha conseguito più lauree in ingegneria all'Università del Michigan e a Stanford, oltre a un MBA dal MIT.
Nella sua nuova posizione, Sahney si unirà al Comitato di Compliance di Inogen e al Comitato per le Nomine e la Governance. Questa nomina mira a rafforzare la posizione di Inogen come leader globale nella cura respiratoria.
Inogen (NASDAQ: INGN) anunció cambios en su Junta Directiva, efectivos a partir de enero de 2025. Mira Kirti Sahney ha sido nombrada nueva miembro de la junta, mientras que Tom West se retirará después de haber servido desde abril de 2023.
Sahney aporta una experiencia significativa en la industria de dispositivos médicos, actualmente forma parte de la junta de Claria Medical y anteriormente fue Presidenta de la Unidad Operativa de Salud Pélvica de Medtronic (2021-2024). Su experiencia incluye roles como CEO de Hyalex Orthopaedics, posiciones de liderazgo en Smith + Nephew y la co-fundación de Myomo. Posee múltiples títulos en ingeniería de la Universidad de Michigan y Stanford, además de un MBA del MIT.
En su nuevo rol, Sahney se unirá al Comité de Cumplimiento de Inogen y al Comité de Nominaciones y Gobernanza. La designación tiene como objetivo fortalecer la posición de Inogen como líder global en el cuidado respiratorio.
Inogen (NASDAQ: INGN)은 2025년 1월부터 적용되는 이사회의 변경 사항을 발표했습니다. Mira Kirti Sahney가 새로운 이사로 임명되었으며, Tom West는 2023년 4월부터 재직한 후 은퇴할 예정입니다.
Sahney는 현재 Claria Medical의 이사회에서 활동하고 있으며, 이전에는 Medtronic의 골반 건강 사업부 사장(2021-2024)으로 재직하는 등 의료 기기 업계에서 중요한 경험을 가지고 있습니다. 그녀는 Hyalex Orthopaedics의 CEO, Smith + Nephew에서의 리더십 역할, 그리고 Myomo의 공동 창립자 등 다양한 경력을 가지고 있습니다. 미시간 대학교와 스탠포드 대학교에서 여러 공학 학위를 취득했으며, MIT에서 MBA를 보유하고 있습니다.
새로운 역할에서 Sahney는 Inogen의 컴플라이언스 위원회와 추천 및 거버넌스 위원회에 합류할 것입니다. 이번 임명은 Inogen의 호흡기 치료 분야에서의 글로벌 리더로서 입지를 강화하는 것을 목표로 하고 있습니다.
Inogen (NASDAQ: INGN) a annoncé des changements au sein de son Conseil d'Administration, prenant effet en janvier 2025. Mira Kirti Sahney a été nommée nouvelle membre du conseil, tandis que Tom West prendra sa retraite après avoir servi depuis avril 2023.
Sahney apporte une expérience significative dans l'industrie des dispositifs médicaux, occupant actuellement un poste au conseil d'administration de Claria Medical et ayant été précédemment présidente de l'unité opérationnelle santé pelvienne de Medtronic (2021-2024). Son parcours professionnel inclut des fonctions en tant que PDG de Hyalex Orthopaedics, des postes de direction chez Smith + Nephew, ainsi que la cofondation de Myomo. Elle détient plusieurs diplômes en ingénierie de l'Université du Michigan et de Stanford, ainsi qu'un MBA du MIT.
Dans son nouveau rôle, Sahney rejoindra le Comité de conformité d'Inogen et le Comité des nominations et de la gouvernance. Cette nomination vise à renforcer la position d'Inogen en tant que leader mondial dans le domaine des soins respiratoires.
Inogen (NASDAQ: INGN) gab Änderungen im Vorstand bekannt, die ab Januar 2025 wirksam werden. Mira Kirti Sahney wurde als neues Vorstandsmitglied ernannt, während Tom West nach seiner Amtszeit seit April 2023 in den Ruhestand treten wird.
Sahney bringt umfangreiche Erfahrung in der Medizintechnik mit, ist derzeit im Vorstand von Claria Medical tätig und war zuvor Präsidentin der Abteilung für Becken Gesundheitsversorgung von Medtronic (2021-2024). Ihre berufliche Laufbahn umfasst Positionen als CEO von Hyalex Orthopaedics, Führungspositionen bei Smith + Nephew und die Mitbegründung von Myomo. Sie hat mehrere Ingenieurtitel von der University of Michigan und Stanford sowie einen MBA vom MIT.
In ihrer neuen Funktion wird Sahney dem Compliance-Ausschuss von Inogen und dem Nominierungs- und Governance-Ausschuss beitreten. Die Ernennung soll die Position von Inogen als globaler Marktführer in der Atemwegspflege stärken.
- Addition of experienced medical device industry executive to the board
- New director brings diverse leadership experience from multiple medical technology companies
- Strengthening of board expertise in technical and operational aspects
- None.
“We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen,” said Elizabeth Mora, Chairperson of the Board. “Mira’s appointment will further strengthen Inogen’s Board with another talented, experienced, and capable member as we advance our position as a global leader in respiratory care.”
“On behalf of the Board of Directors, I would also like to thank Tom West for his contributions to the Board and Company,” said Ms. Mora. “He has played an important role in the transformation of Inogen over the past two years.”
Mira Sahney serves as a board member of Claria Medical, a privately held minimally invasive surgical tools company. She joined Claria Medical’s board in 2017. Previously, Ms. Sahney served as the President of the Pelvic Health Operating Unit at Medtronic (NYSE: MDT) from 2021 to 2024. Before joining Medtronic, Ms. Sahney served as President, Chief Executive Officer, and Director of Hyalex Orthopaedics, a venture-backed medical device innovator from 2017 to 2021. Prior to Hyalex, she served in leadership roles at Smith + Nephew (LON: SNN), including as Senior Vice President and General Manager of both the Ear, Nose and Throat and the Gynecology businesses. She began her medical technology career as co-founder and President of Myomo, Inc (NYSE: MYO), a wearable medical robotics company addressing neurological disorders.
Ms. Sahney graduated summa cum laude from the University of
“I am extremely grateful to have been provided the opportunity to serve on Inogen’s board at such an exciting time in the Company’s history,” said Mira Sahney. “I look forward to helping Inogen continue to deliver value for shareholders and best-in-class solutions for patients.”
In connection with the appointment, Ms. Sahney will be joining the Compliance Committee as well as the Nominating and Governance Committee of the Board.
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.
For more information, please visit www.inogen.com.
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen’s future business plans, market opportunities, financial outlook, growth strategies, and anticipated operational results, are forward-looking statements. Words such as “aims,” “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to the potential benefits of Inogen’s collaboration with Yuwell; satisfaction of the closing conditions under the securities purchase agreement relating to the equity investment; the timing of closing of the equity investment; market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; and risks associated with international operations. For a detailed discussion of these and other risks that could impact Inogen’s operations and financial performance, please refer to the “Risk Factors” section of its Annual Report on Form 10-K for the period ended December 31, 2023, its Quarterly Report on Form 10-Q for the calendar quarter ended March 31, 2024 and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203209464/en/
Source: Inogen, Inc.
FAQ
When will Mira Kirti Sahney join Inogen's (INGN) Board of Directors?
Which committees will Mira Sahney serve on at Inogen (INGN)?
What was Mira Sahney's role at Medtronic before joining Inogen's (INGN) board?
When is Tom West retiring from Inogen's (INGN) Board of Directors?
